Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Gelisgen, RemiseHas files: No

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Relationship between serum sialic acid levels and prolidase activity with airflow obstruction in patients with COPD
    (LIPPINCOTT WILLIAMS \& WILKINS, 2022-01-01) Uysal, Pelin; Teksoz, Duygu; Aksan, Hulya; Durmus, Sinem; Uslu-Besli, Lebriz; Cuhadaroglu, Caglar; Gelisgen, Remise; Simsek, Gonul; Uzun, Hafize
    Our aim in this study was to evaluate the prognostic significance of sialic acid (SA) and prolidase activity and to evaluate the association between airflow obstruction severity and these parameters in chronic obstructive pulmonary disease (COPD) patients. Ninety-four patients (84 M, 10 F) and 34 healthy subjects (19 M, 15 F) were included into the study. COPD staging was performed to COPD patients according to new global initiative for chronic obstructive lung disease criteria which includes pulmonary function tests, symptoms and hospitalization
  • No Thumbnail Available
    Item
    Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease
    (DOVE MEDICAL PRESS LTD, 2019-01-01) Uysal, Pelin; Simsek, Gonul; Durmus, Sinem; Sozer, Volkan; Aksan, Hulya; Yurt, Sibel; Cuhadaroglu, Caglar; Kosar, Filiz; Gelisgen, Remise; Uzun, Hafize
    Background: Antimicrobial peptides are effectors of host defence against infection and inflammation and can encourage wound repair. Objectives: The objectives of this study were to investigate the plasma antimicrobial peptide LL-37 and nuclear factor-kappaB (NF-kappa B) levels in patients with stable COPD compared with a control group and to highlight their importance in immune inflammation. Methods: One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study. The COPD patients were classified into four groups based on FEV1 (groups I-IV) and also divided into ``low-risk and high-risk{''} groups (groups A-B {[}low risk], C-D {[}high risk]). Results: Plasma LL-37 levels were significantly lower while plasma NF-kappa B levels of the COPD patients were significantly higher than those of the control subjects (P<0.001, both). LL-37 levels were significantly lower in group IV than in groups I, II, and III (P<0.01, all). NF-kappa B levels were significantly higher in groups III and IV than in groups I and II (P<0.05, both). There was a positive correlation between FEV1 and FEV1/FVC in all COPD patients (r=0.742, P<0.001) and in group D (r=0.741, P<0.001). Furthermore, there was an inverse correlation between LL-37 and NF-kappa B in both the groups C (r=-0.566, P<0.001) and D (r=-0.694, P<0.001) and group C+ D combined (r=-0.593, P<0.001). Furthermore, in group C, LL-37 and FEV1 were positively correlated (r=0.633, P<0.001). Conclusion: Our study indicated that plasma LL-37 and NF-kappa B may play an important role in chronic immune inflammation. Decreased LL-37 levels may be particularly high risk for patients in stage IV disease. The role of LL-37 as a target for treatment of the immune system and COPD must be widely evaluated.